An Integrin Binding-defective Mutant of Insulin-like Growth Factor-1 (R36E/R37E IGF1) Acts as a Dominant-negative Antagonist of the IGF1 Receptor (IGF1R) and Suppresses Tumorigenesis but Still Binds to IGF1R-Reference-Cited by-同舟云学术

An Integrin Binding-defective Mutant of Insulin-like Growth Factor-1 (R36E/R37E IGF1) Acts as a Dominant-negative Antagonist of the IGF1 Receptor (IGF1R) and Suppresses Tumorigenesis but Still Binds to IGF1R

Published:2013-07 Issue:27 Volume:288 Page:19593-19603
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Fujita Masaaki,Ieguchi Katsuaki,Cedano-Prieto Dora M.,Fong Andrew,Wilkerson Charles,Chen Jane Q.,Wu Mac,Lo Su-Hao,Cheung Anthony T.W.,Wilson Machelle D.,Cardiff Robert D.,Borowsky Alexander D.,Takada Yoko K.,Takada Yoshikazu

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference30 articles.

1. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors;Stewart;Physiol. Rev,1996

2. Role of the integrin αVβ3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress;Clemmons;Growth Horm. IGF Res,2007

3. Interaction between insulin-like growth factor-I receptor and αVβ3 integrin linked signaling pathways: cellular responses to changes in multiple signaling inputs;Clemmons;Mol. Endocrinol,2005

4. IGF system in cancer: from bench to clinic;Chaves;Anticancer Drugs,2011

5. Integrins: bidirectional, allosteric signaling machines;Hynes;Cell,2002

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The heparin-binding domain of VEGF165 directly binds to integrin αvβ3 and VEGFR2/KDR D1: a potential mechanism of negative regulation of VEGF165 signaling by αvβ3;Frontiers in Cell and Developmental Biology;2024-05-09

2. FGF9, a Potent Mitogen, Is a New Ligand for Integrin αvβ3, and the FGF9 Mutant Defective in Integrin Binding Acts as an Antagonist;Cells;2024-02-07

3. Emerging role of competing endogenous RNA in lung cancer drug resistance;Journal of Chemotherapy;2023-12-20

4. FGF9, a potent mitogen, is a new ligand for integrin αvβ3, and the FGF9 mutant defective in integrin binding acts as an antagonist;2023-12-02

5. The heparin-binding domain of VEGF165 directly binds to integrin αvβ3 and plays a critical role in signaling;2023-11-14